Financial Calendar 2019

Q1 Report, 2019

31 January, 2019

Q2 Report, 2019

30 April, 2019

Annual General Meeting

5 December, 2019

Q3 Report, 2019

31 July, 2019

      Year End Report 2019

31 October, 2019

Financial Calendar 2018

Q1 Report, 2018

31 January, 2018

Q2 Report, 2018

30 April, 2018

Annual General Meeting

5 December, 2018

Q3 Report, 2018

31 July, 2018

      Year End Report 2018

31 October, 2018

Financial Calendar 2017

Interim Report, 2017

31 July, 2017

Year End Report, 2017

31 October, 2017

Year End Report, 2017

31 October, 2017

Annual Report, 2017

14 November, 2017

Annual General Meeting,

5 December, 2017

Sharing Information

Dividends And Transparency

Dividends

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development. There is a risk that future cash flows will not exceed the company’s capital requirements and that future AGMs will not decide on future dividends.

Transparency

Shares in NextCell Pharma AB are traded on Spotlight Markets as per July 2017.

List of 5 largest shareholders as per 2018-08-31

Owners / Shares / Percentage

Diamyd Medical AB* / 1 471 291 / 13,11
Avanza Pension** / 1 267 592 / 11,29
Anders Essen-Möller*** / 547 033/ 4,87
PBKM / 488 562 / 4,35
Bertil Lindkvist / 410 478 / 3,66

* NextCell’s Board Chairman Anders Essen-Möller owns 14.6% of the shares and 36.3 of the votes in Diamyd Medical AB.** Chairman Anders Essen-Möller holds shares corresponding to 4,98 percent (558 885 shares) of votes and capital in NextCell which is managed through Avanza Pension. This is in addition to his directly registered share holdings. *** Anders Essen-Möller is the Board Chairman of NextCell. **** Numbers are close approximations and can deviate slightly form reality

Share price

The current share price is available on Spotlight Stock market. https://spotlightstockmarket.com/sv/bolag/irabout?InstrumentId=XSAT01001768

Documentation

Corporate Governance

Auditor

Bo Åsell Öhrlings PricewaterhouseCoopers AB (PwC) Torsgatan 21, 113 97 Stockholm Bo Åsell is an Authorized Public Accountant and a member of FAR, the institute for the accountancy profession in Sweden

Articles Of Association

Nomination Committee

No information available

Incentive Programmes

NextCell Pharma AB currently has no active incentive programmes.

Documentation

Archived documents from IPO 2017

Documentation

Spotlight Stock Market

NextCell Pharma AB is listed on the Spotlight Stock Market since July 2017.

Link to Spotlight Stock Market

Link to NextCell’s IR page on Spotlight Stock Market

 
Contact Karolinska Institutet Science Park Hälsovägen 7, 141 57 Huddinge info@nextcellpharma.com +46 (0)8 735 55 95